thyroid
No description yet: the sentence for this tag has not been written. 10 records carry it: 10 people.
Related tags
10 records
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
Bryan R. Haugen Professor of Medicine and Head of Endocrinology, University of Colorado · University of Colorado Cancer Center Colorado endocrinologist who chaired the 2015 American Thyroid Association guidelines, the reference for how thyroid nodules and differentiated thyroid cancer are diagnosed and treated. | Papillary thyroid cancer, Follicular thyroid cancer, Thyroid cancer | none | guidelines | ||
Julien Hadoux Endocrine oncologist, Gustave Roussy · Gustave Roussy Paris endocrine oncologist who was lead author of LIBRETTO-531, the trial that showed the selective RET inhibitor selpercatinib beats older kinase inhibitors as first treatment for advanced medullary thyroid cancer. | Medullary thyroid cancer, Thyroid cancer | none | targeted-therapy, trialist | ||
Keith C. Bible Medical oncologist, Mayo Clinic · Mayo Clinic Mayo Clinic oncologist who chaired the American Thyroid Association guidelines for anaplastic thyroid cancer, one of the fastest-growing human cancers. | Anaplastic thyroid cancer, Thyroid cancer | none | guidelines | ||
Lori J. Wirth Medical Director, Center for Head and Neck Cancers, Massachusetts General Hospital Cancer Center · Massachusetts General Hospital Cancer Center Led LIBRETTO-001 in thyroid cancer, which made selpercatinib the first RET-selective drug approved for RET-driven tumours. | Thyroid cancer, Head and neck squamous cell carcinoma | none | ret, targeted-therapy | ||
Marcia S. Brose Chair of Medical Oncology, Sidney Kimmel Cancer Center at Jefferson Health · Sidney Kimmel Comprehensive Cancer Center at Jefferson Health Led DECISION, the trial that made sorafenib the first approved targeted drug for radioiodine-refractory thyroid cancer. | Thyroid cancer | none | targeted-therapy | ||
Maria E. Cabanillas Professor of Endocrine Neoplasia and Hormonal Disorders, MD Anderson Cancer Center · MD Anderson Cancer Center Turned anaplastic thyroid cancer from a death sentence into a treatable disease with BRAF-targeted therapy and neoadjuvant strategies. | Thyroid cancer | none | braf, neoadjuvant | ||
Martin Schlumberger Emeritus Professor of Oncology, Gustave Roussy and Université Paris-Saclay · Gustave Roussy Led SELECT (lenvatinib) and the ESTIMABL trials that showed many thyroid cancer patients can have lower radioiodine doses or none at all. | Thyroid cancer | none | radioiodine, de-escalation | ||
Rossella Elisei Professor of Endocrinology, University of Pisa · University of Pisa / Azienda Ospedaliero-Universitaria Pisana Pisa endocrinologist who led EXAM, the trial that established cabozantinib for progressive medullary thyroid cancer, and who has studied RET mutations in the disease for decades. | Medullary thyroid cancer, Thyroid cancer | none | targeted-therapy, trialist | ||
Samuel A. Wells Jr. Endocrine surgeon and clinical investigator · National Cancer Institute (NIH) American surgeon who pioneered removing the thyroid in children with inherited RET mutations before cancer develops, led ZETA, the trial that established vandetanib for medullary thyroid cancer, and chaired the American Thyroid Association guideline for the disease. | Medullary thyroid cancer, Thyroid cancer | none | surgery, trialist | ||
Vivek Subbiah Medical oncologist and Chief of Early-Phase Drug Development, Sarah Cannon Research Institute Early-phase trialist who led the study showing dabrafenib and trametinib work in BRAF-mutant anaplastic thyroid cancer, the first approved treatment for that disease, and many of the RET inhibitor trials. | Anaplastic thyroid cancer, Thyroid cancer, Medullary thyroid cancer | none | targeted-therapy, early-phase, trialist |